AbbVieABBV
ABBV
About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Employees: 50,000
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 12 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 393 | Existing positions closed: 131
5% more funds holding
Funds holding: 3,449 [Q3] → 3,637 (+188) [Q4]
1.68% more ownership
Funds ownership: 70.35% [Q3] → 72.04% (+1.68%) [Q4]
7% more repeat investments, than reductions
Existing positions increased: 1,479 | Existing positions reduced: 1,382
6% more call options, than puts
Call options by funds: $3.18B | Put options by funds: $2.99B
5% less capital invested
Capital invested by funds: $244B [Q3] → $232B (-$12.2B) [Q4]
20% less funds holding in top 10
Funds holding in top 10: 207 [Q3] → 165 (-42) [Q4]
Research analyst outlook
12 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$190
3%
downside
Avg. target
$216
11%
upside
High target
$250
28%
upside
12 analyst ratings
9 positive
75%
3 neutral
25%
0 negative
0%
Guggenheim Vamil Divan 40% 1-year accuracy 12 / 30 met price target | 11%upside $216 | Buy Maintained | 29 Apr 2025 |
Evercore ISI Group Gavin Clark-Gartner 42% 1-year accuracy 5 / 12 met price target | 5%upside $205 | Outperform Maintained | 28 Apr 2025 |
Morgan Stanley Terence Flynn 50% 1-year accuracy 11 / 22 met price target | 28%upside $250 | Overweight Maintained | 28 Apr 2025 |
Cantor Fitzgerald Carter Gould 39% 1-year accuracy 12 / 31 met price target | 8%upside $210 | Overweight Initiated | 22 Apr 2025 |
Goldman Sachs Asad Haider 100% 1-year accuracy 2 / 2 met price target | 1%downside $194 | Neutral Assumed | 8 Apr 2025 |
Financial journalist opinion
Based on 109 articles about ABBV published over the past 30 days
Positive
CNBC
6 hours ago
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom
Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.
Positive
Seeking Alpha
1 day ago
Best Dividend Aristocrats For May 2025
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Edison (+25.65%), Cardinal Health (+17.82%), and Coca-Cola (+16.18%). 33 out of 69 Dividend Aristocrats have announced dividend increases in 2025, with an average growth rate of 4.33%.
Neutral
CNBC Television
1 day ago
Final Trades: Netflix, Abbvie, iShares U.S. Industrials ETF and Sherwin Williams
The Fast Money team just dropped their Final Trades — find out what's catching their eye now!
Neutral
GlobeNewsWire
1 day ago
Levi & Korsinsky Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 – ABBV
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.
Negative
Benzinga
1 day ago
Stock Of The Day: AbbVie's Rally Looks Stretched — Could A Reversal Be Next?
AbbVie Inc. ABBV is trading higher Tuesday. The stock has been in an uptrend.
Positive
Zacks Investment Research
1 day ago
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Positive
Zacks Investment Research
1 day ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Neutral
Accesswire
1 day ago
Shareholders That Lost Money on Cerevel Therapeutics Holdings, Inc. (ABBV) Should Contact Levi & Korsinsky about Pending Class Action - ABBV
NEW YORK, NY / ACCESS Newswire / April 29, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cerevel-therapeutics-holdings-inc-lawsuit-submission-form?prid=145953&wire=1 or contact Joseph E. Levi, Esq.
Neutral
PRNewsWire
1 day ago
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)
– RINVOQ (upadacitinib) is now the first and only oral Janus Kinase (JAK) inhibitor approved for the treatment of GCA in adults – Also known as temporal arteritis, GCA is the most common vasculitis affecting adults in Western countries 2 – This marks the ninth approved indication for RINVOQ in the U.S., across rheumatology, gastroenterology, and dermatology1 NORTH CHICAGO, Ill. , April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA).1 This comes after the European Commission recently granted marketing authorization of RINVOQ for the treatment of GCA in adult patients.
Neutral
PRNewsWire
1 day ago
Levi & Korsinsky Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - ABBV
NEW YORK , April 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud.
Charts implemented using Lightweight Charts™